1. Home
  2. VNO vs ROIV Comparison

VNO vs ROIV Comparison

Compare VNO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VNO
  • ROIV
  • Stock Information
  • Founded
  • VNO 1946
  • ROIV 2014
  • Country
  • VNO United States
  • ROIV United Kingdom
  • Employees
  • VNO N/A
  • ROIV N/A
  • Industry
  • VNO Real Estate Investment Trusts
  • ROIV Biotechnology: Pharmaceutical Preparations
  • Sector
  • VNO Real Estate
  • ROIV Health Care
  • Exchange
  • VNO Nasdaq
  • ROIV Nasdaq
  • Market Cap
  • VNO 7.3B
  • ROIV 8.6B
  • IPO Year
  • VNO N/A
  • ROIV N/A
  • Fundamental
  • Price
  • VNO $42.15
  • ROIV $14.18
  • Analyst Decision
  • VNO Hold
  • ROIV Strong Buy
  • Analyst Count
  • VNO 11
  • ROIV 4
  • Target Price
  • VNO $38.64
  • ROIV $15.50
  • AVG Volume (30 Days)
  • VNO 2.0M
  • ROIV 6.8M
  • Earning Date
  • VNO 11-03-2025
  • ROIV 11-11-2025
  • Dividend Yield
  • VNO 1.76%
  • ROIV N/A
  • EPS Growth
  • VNO 4453.28
  • ROIV N/A
  • EPS
  • VNO 4.07
  • ROIV N/A
  • Revenue
  • VNO $1,889,783,000.00
  • ROIV $23,233,000.00
  • Revenue This Year
  • VNO N/A
  • ROIV N/A
  • Revenue Next Year
  • VNO $2.94
  • ROIV $281.14
  • P/E Ratio
  • VNO $10.33
  • ROIV N/A
  • Revenue Growth
  • VNO 0.58
  • ROIV N/A
  • 52 Week Low
  • VNO $29.68
  • ROIV $8.73
  • 52 Week High
  • VNO $46.63
  • ROIV $14.48
  • Technical
  • Relative Strength Index (RSI)
  • VNO 63.81
  • ROIV 75.19
  • Support Level
  • VNO $41.63
  • ROIV $13.81
  • Resistance Level
  • VNO $43.37
  • ROIV $14.48
  • Average True Range (ATR)
  • VNO 1.05
  • ROIV 0.43
  • MACD
  • VNO 0.41
  • ROIV 0.17
  • Stochastic Oscillator
  • VNO 80.97
  • ROIV 88.76

About VNO Vornado Realty Trust

Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Share on Social Networks: